Annals of Hematology

, Volume 89, Issue 5, pp 489–497

Bortezomib, thalidomide, dexamethasone induction therapy followed by melphalan, prednisolone, thalidomide consolidation therapy as a first line of treatment for patients with multiple myeloma who are non-transplant candidates: results of the Korean Multiple Myeloma Working Party (KMMWP)

  • Hyeon-Seok Eom
  • Yeo-Kyeoung Kim
  • Joo-Seop Chung
  • Kihyun Kim
  • Hyo Jung Kim
  • Ho Young Kim
  • Jong-Youl Jin
  • Young-Rok Do
  • Suk-Joong Oh
  • Cheolwon Suh
  • Chu-Myong Seong
  • Chul Soo Kim
  • Dong Soon Lee
  • Jae Hoon Lee
Original Article

Abstract

Bortezomib (VELCADE®), thalidomide and dexamethasone (VTD), as well as melphalan, prednisolone, and thalidomide (MPT) therapy, are highly effective in patients with multiple myeloma. We evaluated the responses and survival times of 35 patients treated with VTD followed by MPT. All patients were newly diagnosed and non-transplantation candidates. Patients received six cycles of VTD, which were followed by eight cycles of MPT. Approximately 97% of patients exhibited early responses to therapy, as early as the second cycle of VTD. Thirty percent of the responses were high quality, which was defined as a complete response (CR), a near-CR or a very good partial response. High-risk patients were defined as patients with any of the following aberrations: del(13), t(4;14), or del(17p). The remaining patients were defined as standard risk. Eleven high-risk patients showed 100% response rates, including 91% high-quality responses. In contrast, 13 standard-risk patients exhibited 92% response rates, including 61% high-quality responses. The overall 2-year survival rates were 60% in high-risk patients and 85% in standard-risk patients, which was not significantly different. As a first-line therapy, VTD followed by MPT has the potential to provide high-quality responses with durable remission among elderly and high-risk patients (clinicaltrials.gov identifier: NCT00320476).

Keywords

Multiple myeloma Bortezomib Thalidomide High-risk Elderly patients 

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Hyeon-Seok Eom
    • 1
  • Yeo-Kyeoung Kim
    • 2
  • Joo-Seop Chung
    • 3
  • Kihyun Kim
    • 4
  • Hyo Jung Kim
    • 5
  • Ho Young Kim
    • 5
  • Jong-Youl Jin
    • 6
  • Young-Rok Do
    • 7
  • Suk-Joong Oh
    • 8
  • Cheolwon Suh
    • 9
  • Chu-Myong Seong
    • 10
  • Chul Soo Kim
    • 11
  • Dong Soon Lee
    • 12
  • Jae Hoon Lee
    • 13
  1. 1.Hematology-Oncology Clinic, Center for Specific Organs CancerNational Cancer CenterGoyangSouth Korea
  2. 2.Hematology-OncologyChonnam National University Hwasun HospitalJeollanam-doSouth Korea
  3. 3.Hematology-OncologyPusan National University HospitalBusanSouth Korea
  4. 4.Hematology/Oncology, Department of MedicineSungkyunkwan University School of Medicine, Samsung Medical CenterSeoulSouth Korea
  5. 5.Hematology-OncologyHallym University Medical CenterAnyangSouth Korea
  6. 6.Hemato-OncologyHoly Family HospitalBucheonSouth Korea
  7. 7.Hematology-OncologyDongsan Medical CenterDaeguSouth Korea
  8. 8.Division of Hematology-OncologySamsung Medical Center, Sungkyunkwan University School of MedicineSeoulSouth Korea
  9. 9.Oncology, Asan Medical CenterUniversity of Ulsan College of MedicineSeoulSouth Korea
  10. 10.Hemato-OncologyEwha Woman’s University HospitalSeoulSouth Korea
  11. 11.Comprehensive Cancer CenterInha University HospitalIncheonSouth Korea
  12. 12.Laboratory MedicineSeoul National University HospitalSeoulSouth Korea
  13. 13.Department of Hematology-OncologyGachon University Gil HospitalIncheonSouth Korea

Personalised recommendations